February 23, 2009 -- GeneraMedix, Inc. announced today that it has entered into a definitive agreement to sell its improved formulation of epoprostenol sodium for the intravenous treatment of pulmonary arterial hypertension to Actelion LTD., a biopharmaceutical company with its headquarters in Allschwil/Basel, Switzerland.
The details can be read here.
No comments:
Post a Comment